比索洛尔与缬沙坦治疗顽固性高血压的临床效果比较研究

Comparative study on the clinical effect of Bisoprolol and Valsartan in the treatment of resistant hypertension

目的比较比索洛尔与缬沙坦治疗顽固性高血压的临床效果。方法选取2019年6月至2021年6月安徽省宿州市中医医院收治的顽固性高血压患者96例为研究对象,以随机数字表法将其分为对照组、试验组,各48例。对照组在常规治疗基础上口服缬沙坦,80 mg/次,1次/d;试验组在常规治疗基础上口服比索洛尔,5 mg/次,1次/d。两组均连续治疗4周。比较两组临床疗效及治疗前后舒张压(DBP)、收缩压(SBP)、炎症因子、脂代谢水平,记录两组药物不良反应的发生情况。结果研究过程中,试验组脱落1例,对照组脱落2例。两组临床疗效比较,差异无统计学意义(P>0.05)。治疗后,两组DBP、SBP均低于治疗前,差异有统计学意义(P<0.05)。治疗后,两组超敏C反应蛋白、Salusin-β、基质金属蛋白酶-3均低于治疗前,且试验组低于对照组,差异有统计学意义(P<0.05)。两组治疗前后的总胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇比较,差异无统计学意义(P>0.05)。两组药物不良反应总发生率比较,差异无统计学意义(P>0.05)。结论比索洛尔与缬沙坦治疗顽固性高血压效果相当,均不影响顽固性高血压患者的血脂代谢指标,安全性良好,但比索洛尔在改善顽固性高血压血清炎症因子方面更具优势。

Objective To compare the clinical efficacy of Bisoprolol and Valsartan in the treatment of resistant hypertension.Methods A total of 96 patients with resistant hypertension admitted to Suzhou Hospital of Traditional Chinese Medicine in Anhui Province from June 2019 to June 2021 were selected as the research objects.They were divided into control group and experimental group by random number table method,with 48 cases in each group.The control group was treated with Valsartan,80 mg/time,once a day on the basis of routine treatment.The experimental group was treated with Bisoprolol,5 mg/time,once a day on the basis of routine treatment.Both groups were treated for four weeks.The clinical efficacy,and diastolic blood pressure(DBP),systolic blood pressure(SBP),inflammatory factors,lipid metabolism levels were compared between the two groups before and after treatment,and the occurrence of adverse drug reactions in the two groups was recorded.Results During the study,one case dropped out of the experimental group and two cases dropped out of the control group.There was no significant difference in clinical efficacy between the two groups(P>0.05).After treatment,DBP and SBP of the two groups were lower than those before treatment,and the differences were statistically significant(P<0.05).After treatment,the levels of high-sensitivity C-reactive protein,Salusin-β,and matrix metalloproteinase-3 in the two groups were lower than those before treatment,and those in the experimental group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in total cholesterol,high density lipoprotein cholesterol,and low density lipoprotein cholesterol between the two groups before and after treatment(P>0.05).There was no significant difference in the total incidence of adverse drug reactions between the two groups(P>0.05).Conclusion Bisoprolol and Valsartan have similar efficacy in the treatment of resistant hypertension,and they do not affect the blood lipid metabolism indexes of patients with resistant hypertension,with good safety,but Bisoprolol has more advantages in improving serum inflammatory factors in patients with resistant hypertension.